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• Resistance to at least one ART, 97.8%, 81.9% and 56.6% in FF, SF and RF. 
Any NNRTI resistance, 38.5%, 96.4%, 75.5%, and 53.8% in N, FF, SF, and 
RF. Any PI resistance, 30.8% and 23% in second line and RAL failures






• Uganda is among the countries with the highest burden of HIV-
1 infections, with approximately 1.4 million (6.5%) people living
with HIV/AIDS and 67% of them receiving combined
antiretroviral therapy.
• Like other Low income countries (LICs), it is facing dilemma of
increasing rates of HIV transmitted drug resistance and
acquired drug resistance (DR).
• Despite increasing access to generic Dolutegravir (DTG) in LICs,
data on DTG associated DR in this setting is lacking.
• We evaluated DTG associated DR in (n=400) patients who are
ART naïve (N), and those failing on first line(FF), second line (SF)
and RAL based third line (RF) treatments in Uganda.
• Deep sequencing using Illumina (Miseq) was done in (n=68) of
these patients.
• Patients with virological failure ( viral load of ≥ 1000 copies/ml)
were selected for the study
• HIV-1 integrase enzyme was amplified from extracted RNA and
sequenced using Sanger and Miseq platforms.
• Drug susceptibility was interpreted using HIV-1 genotyping
resistance interpretation of Stanford HIV database
(https://hivdb.stanford.edu) and Scueal program was used for
HIV-1 subtype classifications.
• Joint Clinical Research Centre, Kampala, Uganda
• Dr Eric J Arts laboratory, department of Microbiology and
Immunology, Schulich School of Medicine & Dentistry University
of Western Ontario, London, Ontario, Canada
1Department of Microbiology and Immunology, Schulich School of Medicine & Dentistry University of Western Ontario, London, Ontario, Canada
2Joint Clinical Research Centre, Kampala, Uganda
HIVdb drug susceptibility for all patient groups
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HIV-1 infected patients failing on RAL-based regimen with primary and/or 
secondary (compensatory) INSTI mutations
Primary/secondary mutations n (%) DTG RAL EVG
M50I/L/MR 1(3.0) S S S
M50I,L74I 1(3.0) S S S
T97A 1(3.0) S P P
T97A,G163R,L74M 3(8.8) S L L
N155H 2(6.0) P H H
N155H,T97A 1(3.0) P H H
N155H,T97AT 1(3.0) P H H
N155H,T97A,E157Q,L74I 1(3.0) P H H
N155H,E157Q,G163R,M50L,L74I 1(3.0) P H H
Y143R,T97A 2(6.0) S H L
Y143R,T97AT,G163R 1(3.0) P H I
Y143R,T97A,M50I,L74LM 1(3.0) P H I
E138A,T97A,V151A 1(3.0) P I I
E138K,G140A,S147G,Q148K 1(3.0) H H H
T66A,T97A,G163R,L74M 1(3.0) S I H
The work flow chart of the patient numbers and their respective 
groups
HIV-1 genotypic resistance interpretation based on Sanger 
sequencing
Illumina Sanger
S147G, G140A, E138K, Q148K, S230N, M50L S147G, G140A, E138K, Q148K
N155H, Y143H, M50I N155H
Y143R, T97A, G163R Y143R, T97A, 
T97A, L74M, M50I T97A, L74LM
T97A, N155H, L74I T97A, N155H, L74I
T97A, L74M, V151I, G163R T97A
T97A, M50I, N155H T97AT, N155H
N155H, V151I N155H





T97A, L74M, V151I, G163R G163R, T97A, L74LM, V151I
M50L M50L
M50L, L74M, T97A, V151I, G163R L74M, T97A, V151I, G163R
M50I NONE
Subtype No. (%)




A D C A/D Other d
cART naïve (n = 87) None 4.64 42(47.1) 17(19.5) 3(3.4) 9(10.3) 17(19.5)
Failing First-line cART (n = 158) AZT, 3TC, NVP (38) 0.54 14(36.9) 11(28.9) 4(10.5) 2(5.3) 7(18.4)
TDF, 3TC, EFV (34) 1.21 14(41.2) 10(29.4) 2(5.9) 1(2.9) 7(20.6)
AZT, 3TC, EFV (18) 1.31 18(44.4) 6(33.3) 1(5.6) 1(5.6) 2(11.1)
TDF, 3TC, FTC (15) 0.43 1(20) 1(20) 1(20) 0(0.0) 2(40)
Other (14) 7.5 5(35.7) 5(35.7) 2(14.3) 2(14.3) 0(0.0)
3TC, D4T, NVP (13) 2.2 8(61.5) 1(7.7) 0(0.0) 1(7.7) 3(23.1)
ABC, 3TC, NVP (10) 2.56 4(40) 1(10) 1(10) 1(10) 3(30)
ABC, 3TC, EFV (7) 0.64 7(100) 0(0.0) 0(0.0) 0(0.0) 0(0.0)
TDF, 3TC, NVP (6) 0.97 0(0.0) 3(50) 0(0.0) 1(16.7) 2(33.3)
3TC, AZT, NVP (4) 2.22 0(0.0) 1(25) 1(25) 1(25) 1(25)
d4T, 3TC, NVP (3) 0.97 0(0.0) 3(100) 0(0.0) 0(0.0) 0(0.0)
AZT, 3TC, ABC (2) ND 0(0.0) 1(50) 0(0.0) 0(0.0) 1(50)
FTC, TDF, EFV (2) 0.7 1(50) 0(0.0) 0(0.0) 0(0.0) 1(50)
TDF, ABC, AZT (n = 2) ND 1(50) 0(0.0) 0(0.0) 0(0.0) 1(50)
Failing Second-line cART (n = 121) TDF, 3TC, LPVr (30) 1.22 13(43.3) 4(13.3) 2(6.7) 2(6.7) 9(30)
TDF, 3TC, ATVr (30) 2.2 14(46.7) 7(23.3) 1(3.3) 2(6.7) 6(20)
ABC, 3TC, LPVr (25) 2.13 12(48) 8(32) 1(4) 0(0.0) 4(16)
ABC, 3TC, ATVr (25) 3.64 3(60) 0(0.0) 0(0.0) 0(0.0) 2(40)
AZT, 3TC, LPVr (13) 7.82 4(30.7) 3(23.1) 0(0.0) 3(23.1) 3(23.1)
LPVr (7) 0.05 3(42.9) 4(57.1) 0(0.0) 0(0.0) 0(0.0)
AZT, 3TC, ATVr (6) 2.53 4(66.7) 2(33.3) 0(0.0) 0(0.0) 0(0.0)
Other (5) 0.7 1(20) 1(20) 0(0.0) 1(20) 2(40)
Failing RAL-based cART (n =34) RAL, LPVr (16) 2.2 7(43.75) 4(25) 0(0.0) 3(18.75) 2(12.5)
Other (6) 0.3 4(66.6) 1(16.7) 0(0.0) 0(0.0) 1(16.7)
RAL, DRVr (5) 9.5 4(80) 1(20) 0(0.0) 0(0.0) 0(0.0)
RAL, ATVr (2) 8.5 1(50) 1(50) 0(0.0) 0(0.0) 0(0.0)
RAL, TDF, 3TC, LPVr (2) 2.7 2(100) 0(0.0) 0(0.0) 0(0.0) 0(0.0)
TDF, 3TC, RAL, DRVr (2) 0.03 1(50) 1(50) 0(0.0) 0(0.0) 0(0.0)
RAL, ETR, DRVr (2) 1.1 2(100) 0(0.0) 0(0.0) 0(0.0) 0(0.0)
Clinical and virological characteristics of the patients
On average, subtype A, 45.7%, subtype D, 25.2%, subtype C, 4.75%
and recombinant AD, 7.5%.
In all 400 patients; Y143R (0.75%), Q148K (0.25%), N155H (1.5%),
E138A/K (0.5%), G140A (0.25%), S147G (0.25%). Accessory mutations;
T97A (8.75%), M50I 6.5%), L74M/I (3%), E157Q (1.25%), V151I/A (2%),
G163R (1.5%). In bold, are integrase major resistance mutations.
























































Y143R/H, Q148K/R, G140A/E, 1.47%, 3.0%, S147G, 1.47%, 1.47% , T66K,






























Comparison of INSTIs accessory DRMs detected by Sanger and 
Illumina
R263G, 0.0%, 4.4%, S230N, 0.0%, 1.47%, G118V, 0.0%, 1.47%,
T97A/S, 20.5%, 22.0%, M50I/L, 30.8%, 63.2%, L74M/I, 16.17%,
20.5%, G163R/E/T, 2.94%, 7.35%, V151I, 1.47%, 5.88%, Q95A/R,
1.47%, 3.0%, F121L, 0.0%, 1.47% by sanger and Illumina
respectively.HIVdb program Genotypic resistance interpretation algorithm from
Stanford university HIV drug resistance database was used to predict
the levels of susceptibility. A susceptible genotype is shown in green,
intermediate and high level resistance is shown in yellow and red
respectively.
Genotypic resistance interpretation and scueal HIV subtype















ART naïve First line failures 















A='A', A1='A', A2='A', A3='A', 'A,A1 recombinant'='A', 'A1,A2
recombinant'='A', D='D', 'A,D recombinant'='A,D rec.', 'A3,D
recombinant'='A,D rec.', 'A1,D recombinant'='A,D rec.', 'A2,D
recombinant'='A,D rec.', C=‘C’
Dark green =susceptible [0-10); light green = potential low-
level resistance [10,15); yellow = low-level resistance [15,30);
orange = intermediate resistance [30,60); red = high-level
resistance [60, inf).
No primary DTG DRMs were found in 366 INSTIs naïve 
patients, and only one patient was found to have DTG resistance 
genotype in RAL failures. The very high NNRTIs resistance 
across all patient groups call for introduction of DTG or 
Bictegravir in treatment naïve patients in Uganda
The HIV subtype was predicted using SCUEAL subtype classification
algorithm. Viral loads were assayed using Abbott m2000sp/rt or
Roche COBAS Amplicor Monitor ultrasensitive tests, v1.5.
Comparison of INSTIs major DRMs detected by Sanger and 
Illumina
